한국어
미제공
과학 프로그램 2 일 차
English
한국어
미제공
Explore the Agenda
8:00 am Check-in & Morning Coffee
8:50 am Chair’s Opening Remarks
Outlining the Development of Bispecifics & T-Cell Engagers in Autoimmune Diseases to Expand Their Therapeutics Application
9:00 am Exploring How Cis-Acting PD-1 Bispecific Antibodies Enable Tunable Checkpoint Modulation Through Immune Synapse Sequestration or Recruitment
- Outline the cis-acting PD-1 bispecific framework that enables programmable checkpoint modulation by controlling PD-1 spatial positioning at the immune synapse through defined molecular geometry
- Exploring how this design strategy supports both antagonist and agonist outcomes, linking synapse exclusion or recruitment of PD-1 to distinct signaling states and T-cell functional programs without Fc receptor dependence
- Discussing how this approach establishes a unified path from molecular design and epitope selection to disease-relevant immune modulation across oncology and autoimmune models
9:30 am Outlining ZW1528, a Bispecific Antibody Targeting IL-4Ra & IL-33, Potently Inhibits Key Mediators of Airway Inflammation
- Discuss how ZW1528 high-affinity binding to IL-4Ra and IL-33 mediates potent blockade of IL-4, IL-13, and IL-33 pathways, and drives in vitro inhibition of type 2 and non-type 2 responses in primary immune cells of COPD patients
- Demonstrate that ZW1528 significantly reduces both systemic and local lung inflammation in mice with humanized IL-4/IL-4Ra
- Review ZW152’s good tolerability and favorable pharmacokinetics in the NHP and biomarkers of target blockade
- Unveil how these findings validate the rational design of ZW1528 and support its therapeutic potential across a range of airway inflammatory conditions
10:00 am Refreshment Break
11:00 am Designing Molecules to Decouple Potency From CRS in Autoimmune T-Cell Engagers
- Discover how Y108 is a PEGylated CD3/CD19 T-cell engager derived from the clinically validated blinatumomab platform
- Outline how, by leveraging established PEGylation technology, JY108 is designed to reduce cytokine release syndrome and improve tissue penetration
- Examine preclinical studies in autoimmune disease models that support its potential as a novel B-cell depletion therapy for autoimmune indications
11:30 am Advancing Next-Generation Bispecific Antibodies: From Rigidity to Flexibility for Differentiation & Clinical Translation
- Designing the strategy and target rationale of FlexiBody®, a multi-specific antibody platform
- Engineering considerations to optimize efficacy while mitigating on-target toxicity
- Exploring translational insights supporting clinical development and differentiation
12:00 pm Lunch
1:00 pm Meeting Booking Session
Dedicated time to have pre-scheduled 1-on-1 meetings booked through the event app, enabling deeper discussion and collaboration across the ADC, Bispecific, and TPD
communities.
Pre-scheduled meetings will be available for all attendees on the main conference days from 11:30 – 15:00.
2:00 pm Shaping the Future of Bispecific & T-Cell Engager Design to Improve Patient Outcomes
- Defining the medical and technical unmet needs in bispecific antibodies and ADCs
- Addressing the unmet needs through NanoMab (nanobody-based) solutions
- Outlining the potential market impact and future implications of NanoMab-enabled therapeutics
2:30 pm Reshaping the Patient T-Cell Landscape: Overcoming T-Cell Engager Limitations Through Cytokine Combination Strategies
- Examining key limitations of current T-cell engager therapies, including T-cell exhaustion, suboptimal activation, and durability challenges in solid tumors, and where rational combination strategies are emerging as a solution
- Discussing the scientific rationale for combining T-cell engagers with immunocytokines to reshape the tumor microenvironment and enhance T-cell expansion, activation, and persistence
- Exploring translational and clinical development considerations for advancing cytokine + TCE combinations into phase 2 studies, including biomarker strategy and anticipated indicators of synergy
3:00 pm Refreshment Break
3:30 pm CT-P72/ABP-102: A dual affinity engineered HER2/CD3 tetravalent bispecific antibody with potential to overcome therapeutic barriers in HER2 high tumors with distinct potency, safety, and selectivity
- CT-P72/ABP-102 bound specifically to human and cynomolgus macaque HER2 and CD3, and exhibited lower binding to both HER2 and CD3 compared to its parental antibody ABP 10.0
- CT-P72/ABP-102 demonstrated activity in T-cell activation, PBMC-mediated cytotoxicity, and cytokine release experiments comparable to the parental bispecific antibody with HER2 high-expressing tumor target cells but exhibited reduced activity with HER2-low tumor target cells
- CT-P72/ABP-102 was well tolerated, with the NOAEL determined to be 80 mg/kg when administered twice a week for 4 weeks (total of 8 doses).
4:00 pm A First-in-Class CD39-TGFb-trap Bispecific Antibody With Strong Single Agent Clinical Activity in Solid Tumors
- Outlining the biological rationale and design of the molecule
- Discussing MoA and preclinical data
- Sharing Phase I clinical efficacy and safety data, as well as detailed clinical data in desmoid tumor